ReviewHematology. American Society of Hematology. Education Program2019
Is there a role for immunosuppression in antiphospholipid syndrome?
Review in Hematology. American Society of Hematology. Education Program, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Monoclonal Gammopathy of Thrombotic Significance.American journal of hematology · 2026Review
- Neonatal intracardiac thrombosis secondary to transplacental transfer of maternal antiphospholipid antibodies-a case report and review of the literature.Research and practice in thrombosis and haemostasis · 2025Article
- Insight into antiphospholipid syndrome: the role and clinical utility of neutrophils extracellular traps formation.Thrombosis journal · 2024Article
- Antiphospholipid Antibodies Are Major Risk Factors for Non-Thrombotic Cardiac Complications in Systemic Lupus Erythematosus.Biomedicines · 2024Article
- Catastrophic Antiphospholipid Syndrome.International journal of molecular sciences · 2024Review
- Article
- Article
- The Effect of Rituximab on Antiphospholipid Titers in Patients with Antiphospholipid Syndrome.TH open : companion journal to thrombosis and haemostasis · 2023Article
- Heart Valve Involvement in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Study of a Single Centre.Journal of clinical medicine · 2023Article
- Corticosteroids, Plasmapheresis, Argatroban, Rituximab, and Sirolimus Provided Clinical Benefit for Catastrophic Antiphospholipid Syndrome in a Patient with a History of Heparin-Induced Thrombocytopenia.Case reports in rheumatology · 2023Article
- Antiphospholipid Antibodies and Lipids in Hematological Malignancies.International journal of molecular sciences · 2022Review
- Low dose versus standard dose rituximab for the treatment of antiphospholipid syndrome: A pilot study from a tertiary medical center.Frontiers in immunology · 2022Article
- Successful Treatment of Catastrophic Antiphospholipid Syndrome Using Rituximab: Case Report and Review of the Literature.Medicina (Kaunas, Lithuania) · 2021Review
- The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets.International journal of molecular sciences · 2021Article
- Characteristics and Management of Autoimmune Disease-Associated Cerebral Venous Sinus Thrombosis.Frontiers in immunology · 2021Review
- Management of Non-criteria Manifestations in Antiphospholipid Syndrome.Current rheumatology reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombosis, pregnancy morbidity, or nonthrombotic manifestations in patients with persistently positive antiphospholipid antibodies (aPL). Conventional APS treatment focuses on antithrombotic strategies, which are usually ineffective for the microvascular and nonthrombotic manifestations of aPL. Using a case-based presentation, this review focuses on the role of immunosuppression in nonobstetric APS, including B-cell inhibition (rituximab, belimumab, and bortezomib), complement inhibition (eculizumab), mechanistic target of rapamycin inhibition (sirolimus), vascular endothelial cell modulation (defibrotide), statins, and traditional rheumatologic disease-modifying agents (hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.